Opinion | Editorials, Opinion Pieces Address FDA Regulation Practices - Kaisernetwork.org
Opinion | Editorials, Opinion Pieces Address FDA Regulation Practices - Kaisernetwork.org: "Daily Health Policy Report
Opinion | Editorials, Opinion Pieces Address FDA Regulation Practices
[Nov 29, 2004]
Several editorials and opinion pieces recently addressed FDA's prescription drug monitoring system. Following are summaries.
Editorials
Akron Beacon Journal: Concerns that FDA 'can no longer adequately monitor' new prescription drugs for 'adverse side effects after [they] are on the market' lends 'merit' to the 'growing call to create a separate office that would monitor drugs,' a Beacon Journal editorial states. 'Ultimately, the financial health of drug companies lies in public confidence about the safety of their drugs,' the editorial concludes (Akron Beacon Journal, 11/29).
Atlanta Journal-Constitution: '[P]ublic confidence' in FDA is 'eroding,' and the 'tentative steps outlined' by the agency for reforms 'seem insufficient to convince doctors and the public that [it] is capable of effectively monitoring unexpected health and safety problems once ... drugs are in patients' hands,' according to a Journal-Constitution editorial. The editorial states, 'Congress should consider creating an agency independent of [FDA] to keep watch over an industry that now seems more interested in selling directly to consumers than to physicians' (Atlanta Journal-Constitution, 11/24).
Bergen Record: The 'only way to restore confidence in the FDA and to safeguard the public's health' is for Congress to 'create a board independent of both the FDA and the pharmaceutical industry to monitor the safety of drugs after they are approved,' the Record states in an editorial (Bergen Record, 11/28).
B"
Opinion | Editorials, Opinion Pieces Address FDA Regulation Practices
[Nov 29, 2004]
Several editorials and opinion pieces recently addressed FDA's prescription drug monitoring system. Following are summaries.
Editorials
Akron Beacon Journal: Concerns that FDA 'can no longer adequately monitor' new prescription drugs for 'adverse side effects after [they] are on the market' lends 'merit' to the 'growing call to create a separate office that would monitor drugs,' a Beacon Journal editorial states. 'Ultimately, the financial health of drug companies lies in public confidence about the safety of their drugs,' the editorial concludes (Akron Beacon Journal, 11/29).
Atlanta Journal-Constitution: '[P]ublic confidence' in FDA is 'eroding,' and the 'tentative steps outlined' by the agency for reforms 'seem insufficient to convince doctors and the public that [it] is capable of effectively monitoring unexpected health and safety problems once ... drugs are in patients' hands,' according to a Journal-Constitution editorial. The editorial states, 'Congress should consider creating an agency independent of [FDA] to keep watch over an industry that now seems more interested in selling directly to consumers than to physicians' (Atlanta Journal-Constitution, 11/24).
Bergen Record: The 'only way to restore confidence in the FDA and to safeguard the public's health' is for Congress to 'create a board independent of both the FDA and the pharmaceutical industry to monitor the safety of drugs after they are approved,' the Record states in an editorial (Bergen Record, 11/28).
B"
posted by Chris Placitella at 9:05 AM
0 Comments:
Post a Comment
<< Home